Figure 4.

Kaplan‐Meier curve for the primary and secondary endpoints, ischemic strokes/SEs, major bleeding, new onset dementia, cardiac events, and all‐cause mortality between the warfarin and DOAC users. The clinical events were assessed among 667 age, BW, CHADS₂ score, and CHA₂DS₂‐VASc score‐matched DOAC and warfarin users